Literature DB >> 32146422

Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs.

Wenxiao Jiang1, Jun Xia2, Shangdan Xie1, Ruanmin Zou1, Shuya Pan1, Zhi-Wei Wang3, Yehuda G Assaraf4, Xueqiong Zhu5.   

Abstract

Chemoresistance including intrinsic and acquired anticancer drug resistance continues to be a primary hindrance towards curative cancer treatment. Therefore, deciphering the underlying molecular mechanisms is of paramount importance required towards the overcoming of chemoresistance. Cumulative evidence revealed that long non-coding RNAs (lncRNAs) play a pivotal role in conferring anticancer drug resistance upon a broad spectrum of cancers. Hence, numerous lncRNAs are recognized as novel biomarkers and therapeutic targets in the diagnosis and treatment of malignancies, which urges us to comprehensively delineate the critical functions of lncRNAs in chemoresistance. In this respect, we herein succinctly elucidate the molecular mechanisms by which lncRNAs modulate their downstream targets to mediate cancer chemoresistance. Therefore, the current review may provide a significant basis for the future conquering of chemoresistance via targeting lncRNAs in cancer therapeutics.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Chemotherapy; Drug resistance; Long non-coding RNA; Pathway; Target; miRNA

Mesh:

Substances:

Year:  2020        PMID: 32146422     DOI: 10.1016/j.drup.2020.100683

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  37 in total

Review 1.  Long noncoding RNA loss in immune suppression in cancer.

Authors:  Qingsong Hu; Sergey D Egranov; Chunru Lin; Liuqing Yang
Journal:  Pharmacol Ther       Date:  2020-05-29       Impact factor: 12.310

Review 2.  The role of lncRNA OIP5-AS1 in cancer development and progression.

Authors:  Cheng Zheng; Man Chu; Qiuli Chen; Cheng Chen; Zhi-Wei Wang; Xiao Chen
Journal:  Apoptosis       Date:  2022-03-22       Impact factor: 4.677

Review 3.  The functions of lncRNAs in the HPV-negative cervical cancer compared with HPV-positive cervical cancer.

Authors:  Yi Liu; Hejing Liu; Bo Sheng; Shuya Pan; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Apoptosis       Date:  2022-08-18       Impact factor: 5.561

4.  CACNA1C-AS2 inhibits cell proliferation and suppresses cell migration and invasion via targeting FBXO45 and PI3K/AKT/mTOR pathways in glioma.

Authors:  Tong Cao; Yue Cui; Yingying Wang; Linhui Wu; Ke Yu; Kai Chen; Jun Xia; Yuyun Li; Zhiwei Peter Wang; Jia Ma
Journal:  Apoptosis       Date:  2022-08-29       Impact factor: 5.561

Review 5.  Anticancer drug resistance: An update and perspective.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Drug Resist Updat       Date:  2021-12-16       Impact factor: 18.500

Review 6.  Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications.

Authors:  Huibin Song; Dongcheng Liu; Shaowei Dong; Leli Zeng; Zhuoxun Wu; Pan Zhao; Litu Zhang; Zhe-Sheng Chen; Chang Zou
Journal:  Signal Transduct Target Ther       Date:  2020-09-08

Review 7.  Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.

Authors:  Ya-Nan Pi; Wen-Cai Qi; Bai-Rong Xia; Ge Lou; Wei-Lin Jin
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 8.786

8.  PDS5B inhibits cell proliferation, migration, and invasion via upregulation of LATS1 in lung cancer cells.

Authors:  Hui Xu; Wenjing Zhou; Fan Zhang; Linhui Wu; Juan Li; Tongtong Ma; Tong Cao; Chaoqun Lian; Jun Xia; Peter Wang; Jia Ma; Yuyun Li
Journal:  Cell Death Discov       Date:  2021-06-21

Review 9.  Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.

Authors:  Abdulaziz B Hamid; Ruben C Petreaca
Journal:  Cancers (Basel)       Date:  2020-04-09       Impact factor: 6.639

Review 10.  Noncoding RNA therapeutics - challenges and potential solutions.

Authors:  Melanie Winkle; Sherien M El-Daly; Muller Fabbri; George A Calin
Journal:  Nat Rev Drug Discov       Date:  2021-06-18       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.